TY - JOUR AU - Gross, Stefanie AU - Erdmann, Michael AU - Haendle, Ina AU - Voland, Steve AU - Berger, Thomas AU - Schultz, Erwin AU - Strasser, Erwin AU - Dankerl, Peter AU - Janka, Rolf AU - Schliep, Stefan AU - Heinzerling, Lucie AU - Sotlar, Karl AU - Coulie, Pierre AU - Schuler, Gerold AU - Schuler-Thurner, Beatrice T1 - Twelve-year survival and immune correlates in dendritic cell–vaccinated melanoma patients PY - 2017/04/20/ AB - Background. Reports on long-term (≥10 years) effects of cancer vaccines are missing. Therefore, in 2002, we initiated a phase I/II trial in cutaneous melanoma patients to further explore the immunogenicity of our DC vaccine and to establish its long-term toxicity and clinical benefit after a planned 10-year followup. Methods. Monocyte-derived DCs matured by TNFα, IL-1β, IL-6, and PGE2 and then loaded with 4 HLA class I and 6 class II–restricted tumor peptides were injected intradermally in high doses over 2 years. We performed serial immunomonitoring in all 53 evaluable patients. Results. Vaccine-specific immune responses including high-affinity, IFNγ-producing CD4+ and lytic polyfunctional CD8+ T cells were de novo induced or boosted in most patients. Exposure of mature DCs to trimeric soluble CD40 ligand, unexpectedly, did not further enhance such immune responses, while keyhole limpet hemocyanin (KLH) pulsing to provide unspecific CD4+ help promoted CD8+ T cell responses — notably, their longevity. An unexpected 19% of nonresectable metastatic melanoma patients are still alive after 11 years, a survival rate similar to that observed in ipilimumab-treated patients and achieved without any major (>grade 2) toxicity. Survival correlated significantly with the development of intense vaccine injection site reactions, and with blood eosinophilia after the first series of vaccinations, suggesting that prolonged survival was a consequence of DC vaccination. Conclusions. Long-term survival in advanced melanoma patients undergoing DC vaccination is similar to ipilimumab-treated patients and occurs upon induction of tumor-specific T cells, blood eosinophilia, and strong vaccine injection site reactions occurring after the initial vaccinations. TRIAL REGISTRATION. ClinicalTrials.gov NCT00053391. FUNDING. European Community, Sixth Framework Programme (Cancerimmunotherapy LSHC-CT-2006-518234; DC-THERA LSHB-CT-2004-512074), and German Research Foundation (CRC 643, C1, Z2). JF - JCI Insight JA - JCI Insight SN - 2379-3708 DO - 10.1172/jci.insight.91438 VL - 2 IS - 8 UR - https://doi.org/10.1172/jci.insight.91438 PB - The American Society for Clinical Investigation ER -